Catalio Capital Management
New York, New York, United StatesFounded 2020
Catalio Capital Management is a venture capital firm that exclusively focuses on healthcare and life sciences, investing in breakthrough biomedical technologies. Their strategy involves a multi-stage approach, utilizing venture, growth, credit, and public equity strategies to support innovative companies from inception to IPO.
67% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (4 deals in the last 12 months vs 7 prior). Average disclosed round size is $96.9M (across 24 rounds with reported amounts).
Portfolio
24
Fund Size
$2B
Top Stage
Series B
Last 12 Mo
4
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
24 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Somethings | Series A | $19.2M | Feb 2026 |
 Leo Cancer Care | Series C | $40M | Sep 2025 |
 Visby Medical | Growth | $55M | Jun 2025 |
 GlycoEra AG | Series B | $130M | May 2025 |
 Imbria Pharmaceuticals | Series B | $57.5M | Apr 2025 |
 PrognomiQ | Series D | $34M | Nov 2024 |
 Elektrofi, Inc. | Series C | $112.3M | Oct 2024 |
 Orasis Pharmaceuticals | Series D | $78M | Oct 2024 |
| PProto Axiom | Series B | $20M | Aug 2024 |
 Insightec | Growth | $150M | Jun 2024 |
| AAvava | Series B | $35M | Jun 2024 |
| OOnCusp Therapeutics | Series A | $100M | Jan 2024 |
 Avalyn Pharma Inc. | Series C | $175M | Sep 2023 |
 Ratio Therapeutics Inc. | Series A | $20M | Feb 2023 |
 Haystack Oncology | Series A | $56M | Nov 2022 |
 Odyssey Therapeutics, Inc. | Series B | $168M | Oct 2022 |
 Pheast Therapeutics | Series A | $76M | Apr 2022 |
 Sherlock Biosciences | Series B | $80M | Mar 2022 |
 Freenome | Series D | $300M | Dec 2021 |
 Bayesian Health | Unknown | $15M | Jul 2021 |
 PinkDx | Series A | $40M | — |
 Aviceda Therapeutics | Series C | $199.6M | — |
 ATAI Life Sciences | Series C | $125M | — |
 Recursion Pharmaceuticals | Series D | $239M | — |
Top Co-Investors
Logos Capital4 shared
Alexandria Venture Investments3 shared
RA Capital Management3 shared
T. Rowe Price Associates, Inc.3 shared
Novo Holdings3 shared
OrbiMed3 shared
Marshall Wace3 shared
General Catalyst3 shared
SR One3 shared
Perceptive Advisors2 shared
Janus Henderson Investors2 shared
Eventide Asset Management2 shared
Pura Vida Investments2 shared
HBM Healthcare Investment2 shared
F-Prime Capital2 shared
Sofinnova Partners2 shared
Deep Track Capital2 shared
Woodline Partners2 shared
Samsara BioCapital2 shared
Last updated: 12 April 2026